SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACUS ACUSPHERE INC
ACUS 0.000010000.0%Mar 6 3:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Tadsamillionaire11/9/2007 12:30:27 PM
   of 41
 
Acusphere to Present at the AAPS Annual Meeting and Exposition
Friday November 9, 9:38 am ET

WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (NASDAQ:ACUS - News) today announced today that Olinda Carneiro, Ph.D., Scientist in Acusphere's Research Group, is scheduled to present a poster entitled "Preparation of Powder Formulations of Oxcarbezepine for Potential Use in Oral Dosage Forms" at the 2007 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Diego. Dr. Carneiro’s poster focuses on oral dosage formulations of oxcarbazepine developed by Acusphere using its proprietary technology. Oxcarbazepine is the active ingredient in Trileptal®, marketed by Novartis. The drug has been approved for treatment of epilepsy. The oral dosage formulation of oxcarbazepine developed by Acusphere had a smaller and more uniform particle size distribution and enhanced dissolution rate compared to formulations made with traditional pharmaceutical methods. The poster presentation, at the San Diego Convention Center, will take place on Monday, November 12, 2007, beginning at 1:00 PM local time.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext